Why is IgA anti‑tissue transglutaminase (tTG‑IgA) with total IgA the preferred initial test for celiac disease, and what IgG‑based test should be used if the patient is IgA deficient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Celiac Disease Serology: Why tTG-IgA with Total IgA is Preferred, and What to Do in IgA Deficiency

The preferred initial serological test for celiac disease is IgA anti-tissue transglutaminase (tTG-IgA) combined with total IgA measurement, because tTG-IgA has excellent sensitivity and specificity for active celiac disease, but will be falsely negative in patients with IgA deficiency—a condition that occurs 10-20 times more frequently in celiac patients than the general population. 1

Why tTG-IgA is the Gold Standard

tTG-IgA is the cornerstone of celiac serology because it demonstrates high diagnostic accuracy for detecting active celiac disease. When tTG-IgA levels exceed 10 times the upper limit of normal (>10× ULN), the test becomes extraordinarily reliable—when combined with positive endomysial antibody (EMA) in a second sample, the positive predictive value approaches virtually 100%. 1

The test works because tissue transglutaminase is the primary autoantigen in celiac disease, and IgA antibodies against it are produced in response to gluten exposure in genetically susceptible individuals.

The Critical Pitfall: IgA Deficiency

Here's the problem that makes concurrent total IgA testing mandatory: Selective IgA deficiency occurs in approximately 2-3% of celiac disease patients (compared to 0.2% in the general population), making it 10-20 times more common in this population. 1

What Happens in IgA Deficiency:

  • Patients cannot produce IgA antibodies of any kind
  • tTG-IgA will be falsely negative despite active celiac disease
  • You will miss the diagnosis entirely if you don't check total IgA
  • This represents a major diagnostic trap that can delay diagnosis for years

The Algorithm for IgA-Deficient Patients

When total IgA is low or absent, switch to IgG-based testing: 1

  1. IgG deamidated gliadin peptide (DGP-IgG) antibodies
  2. tTG-IgG antibodies

Both tests have demonstrated excellent diagnostic performance in IgA-deficient patients:

  • IgG anti-tTG shows sensitivity of 75-95% and specificity of 94-100% in IgA-deficient celiac patients 2
  • These perform significantly better than the older IgG anti-gliadin antibodies (AGA-IgG), which had poor accuracy (sensitivity 40%, specificity 87%) 2

Important Caveat About IgG Testing:

Do NOT use IgG-based tests (tTG-IgG) in patients with normal IgA levels—the specificity drops dramatically and you'll get false positives. 1 IgG isotype testing for tTG antibody is only appropriate when IgA deficiency is documented.

Why This Two-Step Approach Matters Clinically

The concurrent measurement of total IgA with tTG-IgA creates a fail-safe system:

  • If total IgA is normal and tTG-IgA is negative: Celiac disease is highly unlikely
  • If total IgA is normal and tTG-IgA is positive: Proceed with standard diagnostic pathway
  • If total IgA is low/absent: Immediately pivot to IgG-based testing to avoid missing the diagnosis

Additional Screening Considerations

Given the high prevalence of celiac disease among IgA-deficient individuals, all patients found to have IgA deficiency should be screened for celiac disease, even if asymptomatic. Studies show that approximately 10% of IgA-deficient blood donors test positive for IgG anti-tTG antibodies, and most carry the HLA-DQ2 or DQ8 genes associated with celiac disease. 3

The Bottom Line for Clinical Practice

Always order tTG-IgA AND total IgA together as your initial screening test. This single practice pattern will prevent you from missing celiac disease in the 2-3% of patients who are IgA deficient. When IgA deficiency is identified, immediately reflex to IgG-based testing (DGP-IgG or tTG-IgG) rather than accepting the negative tTG-IgA result at face value. 1

This approach is endorsed by the AGA 2019 guidelines and represents the standard of care for celiac disease screening. 1

References

Related Questions

Which serologic laboratory test should be ordered to evaluate suspected celiac disease in a patient with IgG antibodies?
Does this 32‑year‑old woman, one month postpartum, who is fatigued, has hair loss, peri‑ungual dermatitis/folliculitis, microcytic anemia with low iron stores, normal IgA, negative anti‑tissue transglutaminase IgA but positive anti‑tTG IgG, have celiac disease?
For a child with celiac disease, what tissue transglutaminase immunoglobulin A (tTG‑IgA) level, expressed as a multiple of the laboratory upper limit of normal, is considered positive—three times or five times the ULN?
In a patient with recurrent oral ulcers and epigastric burning, how should I order and interpret tissue transglutaminase (tTG) antibody testing, including IgA status and current gluten intake?
How should a patient with elevated tissue transglutaminase IgA antibodies but a normal duodenal biopsy be managed?
How should visual agnosia be evaluated and managed?
What alternative analgesics can be used for a patient allergic to paracetamol (acetaminophen) and mefenamic acid?
In a patient with systemic lupus erythematosus presenting with a blood pressure of 148/94 mmHg and a temperature of 37.8 °C, what is the appropriate initial management?
What components should be included in the physical examination of a patient with systemic lupus erythematosus (SLE) to assess typical organ system involvement?
In which conditions should an umbilical artery Doppler assessment be performed to monitor the fetus?
In a patient with a dislodged implantable cardioverter‑defibrillator (ICD) lead awaiting funding for re‑implantation, can oral amiodarone be used as a temporary bridge?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.